Highlights From EASL 2014

April 9-13, 2014; London, UK
In this Expert Analysis, Jordan J. Feld, MD, MPH; Paul Y. Kwo, MD; and Stefan Zeuzem, MD, provide a comprehensive review of the most clinically significant new data from the 2014 Annual Meeting of the European Association for the Study of the Liver on the management of hepatitis C, along with downloadable slides.
Jordan J. Feld, MD, MPH
Paul Y. Kwo, MD
Stefan Zeuzem, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: June 12, 2014 Expiration: June 11, 2015

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate the results of recent clinical studies of approved HCV therapies into patient management strategies
  • Evaluate the impact of results of clinical studies of investigational treatments for chronic hepatitis C on future patient management strategies
  • Critically appraise safety data from studies of investigational agents when considering these therapies for patients with chronic hepatitis C
  • Incorporate the results of recent studies into the management of patients with or at risk of advanced liver disease

Acknowledgements

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AbbVie
Gilead Sciences
Janssen Therapeutics

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Jordan J. Feld, MD, MPH

Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received funds for research support from AbbVie, Boehringer Ingelheim, Gilead Sciences, Roche, and Vertex and has received consulting fees from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Vertex.
Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Vertex; has received funds for research support from AbbVie, Bristol-Myers Squibb, Conatus, Gilead Sciences, Janssen, Merck, Roche, and Vertex; and has received fees for non-CME/CE services received directly from a commercial interest or their agents from Merck.
Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has received consulting fees from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis, Roche, Santaris, and Vertex and has received fees for non-CME/CE services received directly from a commercial interest or their agents (e.g., speakers’ bureaus) from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Roche.

Staff

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no significant financial relationships to disclose.
Anna Poppa

Editorial Contributor

Anna Poppa has no significant financial relationships to disclose.
Jenny Schulz, PhD

Senior Managing Editor

Jenny Schulz, PhD, has no significant financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, consults for Pfizer, Inc.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals involved in the care of patients with hepatitis C.

Goal

The goal of this activity is to identify the most clinically significant data from EASL 2014 and translate those data into management strategies for patients with hepatitis C.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 12, 2014, through June 11, 2015:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary from CCO on how providers can act as advocates for increased access to HCV care for persons who use drugs and incarcerated individuals

Oluwaseun Falade-Nwulia, MBBS, MPH Released: December 18, 2019

Watch this CME/MOC-certified video from a live symposium for expert guidance on approaches to improve diagnosis and treatment of HCV, HBV, and NASH.

Paul Y. Kwo, MD
Program Director
Manal F. Abdelmalek, MD, MPH Oluwaseun Falade-Nwulia, MBBS, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits US Physicians: maximum of 1.5 Medical Knowledge MOC point(s) Released: December 17, 2019 Expiration: December 16, 2020

Audio from CCO faculty Dr. Nancy Reau on strategies to address gaps in viral hepatitis care: learn how to prevent HAV and HBV, how to screen for and treat HCV

Nancy Reau, MD Released: December 3, 2019

Downloadable slides on data from AALSD 2019 selected by expert faculty as relevant to care of patients with viral hepatitis or NAFLD/NASH, as reported by Clinical Care Options.

Ira M. Jacobson, MD Nancy Reau, MD Released: December 2, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?